We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biological E. will soon start Phase III trials of its COVID-19 vaccine and plans to produce 75 million to 80 million doses a month from August, its managing director told Reuters.